SUMATRIPTAN | N020626 | GLAXOSMITHKLINE
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Alexander Mauskop FDA-2026-P-0925 · 39 docket documents Alexander Mauskop filed this citizen petition in January 2026 requesting that the FDA amend the prescription status of seven triptan medications—sumatriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, almotriptan, and frovatriptan—to allow their availability as over-the-counter products by | Other | 2026-01-30 | Open | Alexander Mauskop |
Attachment 2 - IMITREX- sumatriptan tablet, film coated RE Suitability Petiti... FDA-2023-P-4784 · 7 docket documents Hyman, Phelps & McNamara, P.C. filed a citizen petition regarding IMITREX (sumatriptan tablet, film coated) requesting a determination of suitability, likely under 21 CFR 314.80 or related regulatory provisions governing the appropriateness of the drug product formulation or manufacturing process fo | Suitability | 2023-10-30 | Denied | Hyman, Phelps & McNamara, P.C. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$18.85
per ea
Lowest NADAC/Unit
$16.42
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 66993008169SUMATRIPTAN 5 MG NASAL SPRAY | $18.85 | EA | Generic | — | 2026-06-17 |
| 66993008269SUMATRIPTAN 20 MG NASAL SPRAY | $16.42 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.